批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/06/16 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/20 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/12/09 |
SUPPL-19(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2015/07/20 |
SUPPL-18(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/05/29 |
SUPPL-17(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2014/05/29 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-8(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2009/12/09 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/12/09 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/05/16 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:RASAGILINE MESYLATE 剂型/给药途径:TABLET;ORAL 规格:EQ 0.5MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021641 |
001 |
NDA |
AZILECT |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
Yes |
No |
AB |
2006/05/16
|
TEVA |
201970 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2016/03/15
|
ORBION PHARMS |
201971 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2017/05/15
|
AUROBINDO PHARMA USA |
201889 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2017/10/30
|
ALKEM LABS LTD |
201892 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2018/07/27
|
CHARTWELL RX |
207004 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2019/03/29
|
MICRO LABS |
206153 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2019/10/04
|
INDOCO |
218163 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2024/04/09
|
SKG PHARMA |
208866 |
001 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 0.5MG BASE |
Prescription |
No |
No |
AB |
2024/06/28
|
MACLEODS PHARMS LTD |
活性成分:RASAGILINE MESYLATE 剂型/给药途径:TABLET;ORAL 规格:EQ 1MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021641 |
002 |
NDA |
AZILECT |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
Yes |
Yes |
AB |
2006/05/16
|
TEVA |
201970 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2016/03/15
|
ORBION PHARMS |
201971 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2017/05/15
|
AUROBINDO PHARMA USA |
201889 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2017/10/30
|
ALKEM LABS LTD |
201892 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2018/07/27
|
CHARTWELL RX |
207004 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2019/03/29
|
MICRO LABS |
206153 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2019/10/04
|
INDOCO |
218163 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2024/04/09
|
SKG PHARMA |
208866 |
002 |
ANDA |
RASAGILINE MESYLATE |
RASAGILINE MESYLATE |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2024/06/28
|
MACLEODS PHARMS LTD |